Ceftriaxone, a new parenteral cephalosporin, in the treatment of urinary tract infections.
Ceftriaxone (CFX), a parenteral cephalosporin which belongs to a new generation of analogues, was studied by means of three experimental designs in patients suffering from flare-up episodes of chronic urinary tract infections. Results obtained in 2 randomized parallel trials showed a cure rate of 75% with CFX in comparison with 33.3% of gentamicin (p less than 0.05). In a third single open study of 18 patients with infections due to gentamicin-resistant strains, 61.1% became persistently negative during all follow-up controls. Drug-related side effects were mild and did not warrant discontinuation of therapy.
D002443:Ceftriaxone; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011897:Random Allocation; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D005839:Gentamicins; D002443:Ceftriaxone